COVID-19 Outcomes in Solid Organ Transplant Recipients Who Received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab Treatment in a Nurse-driven Monoclonal Antibody Program During the Omicron SurgeWilla Cochran, Robin K. Avery, Kristin Freed et al.|Transplantation|2022Cited by 25
Impact of Bebtelovimab Treatment Timing on COVID‐19 Outcomes in Ambulatory Solid Organ Transplant RecipientsSonsoles Salto‐Alejandre, Robin K. Avery, Willa Cochran et al.|Transplant Infectious Disease|2024Cited by 0